Sleep Medicine
-
Moderate to severe OSA increases risk of severe COVID-19
According to critical care specialist Lina Miyakawa, MD, FCCP, the findings are a reminder that OSA “is not just a sleep disorder but a systemic condition with meaningful public health implications.”
-
Explore recent developments in the treatment of sleep disorders
Multiple sessions will focus extensively on the benefits of glucagon-like peptide-1 (GLP-1) agonists in sleep medicine, said Chitra Lal, MD, MBBS, FCCP, Chair of the Sleep Medicine Curriculum Group and Sleep Medicine Network.
-
Coping styles linked to cognitive complaints in OSA
Investigator Tim J.A. Vaessen, MSc, said the findings suggest clinicians should look beyond sleep apnea and mood symptoms when evaluating cognitive complaints.
-
Practical applications of the new CMS national coverage determination guidelines for noninvasive ventilation in COPD
Many durable medical equipment companies have already started applying the new NIPPV criteria, so it is important for clinicians to become familiar with the changes.
-
Oral medications for sleep in nonintubated ICU patients and their impact on delirium
Clinicians rank pharmacologic sleep aids for ICU patients who are not intubated, beginning with those that have the strongest evidence for safety and efficacy.
-
OSA and the Alzheimer’s continuum
OSA is being increasingly recognized as a potential contributor to neurodegeneration, particularly in the preclinical stages of Alzheimer’s disease. As early intervention becomes a priority in Alzheimer’s prevention, sleep disorders are being investigated as modifiable risk factors.
-
For the neuromuscular disease community, ventilation coverage victory doesn’t carry over
Patient advocate Spero Koulouras said he believes CMS home ventilation coverage criteria for patients with disorders such as ALS are still ambiguous enough that private insurers have interpreted them to deny and delay coverage.
-
Reexamining treatment for RLS: What do the new AASM guidelines teach us?
The key clinical takeaway from the new guidelines is that dopamine agonists are no longer first-line therapy for RLS, and gabapentinoids should be used as primary therapy for most patients.
-
Improving compliance in NIV for COPD
High-intensity NIV is vital for patients with COPD with hypercapnic respiratory failure, and success often depends on overcoming patient intolerance.
-
Early treatment with CPAP may reduce dementia risk for patients with OSA
Sreelatha Naik, MD, FCCP, said the apparent benefit of CPAP therapy is not a surprise; however, more studies are needed to determine if treating sleep apnea can truly mitigate the higher risk of dementia.
-
GLP-1 receptor agonists for managing OSA: Practical insights from an endocrinologist-sleep specialist
Brian Wojeck, MD, MPH, outlines the clinical considerations sleep medicine specialists will increasingly need to know to treat patients with obesity-related sleep apnea.
-
Home high-flow nasal cannula therapy
Home high-flow nasal cannula therapy is a promising alternative form of respiratory support to NIV and CPAP. The treatment has been associated with a reduced number of acute exacerbations.
